New paradigms in immunosuppression.
With the decrease in donor quality and the increase in recipient co-morbidities, transplantation immunosuppression is changing. New paradigms in transplantation include co-stimulation, lymphocyte retrafficking, and inhibiting antibody production. With these new paradigms come new immunosuppressive agents. While these new agents show great promise, their use in day-to-day clinical transplantation remains to be seen.
Isotechnika Inc., Edmonton, Alberta. robert.huizinga@isotechnika.com
Robert
R
Huizinga
Therese
T
Voyer
D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000276:immunology / Q000627:therapeutic use; D060908:CTLA-4 Antigen; D015897:Comorbidity; D000068876:Fingolimod Hydrochloride; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000276:immunology / Q000627:therapeutic use; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods* / Q000639:trends; D007166:Immunosuppressive Agents / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*; D016377:Organ Transplantation / Q000009:adverse effects; D011409:Propylene Glycols / Q000276:immunology / Q000627:therapeutic use; D013110:Sphingosine / Q000031:analogs & derivatives; D014181:Transplantation Immunology / Q000187:drug effects / Q000276:immunology*
D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine